Skip to content
StackItSmart
CCase reports / series
High riskCardiotoxicNeuropsychiatric

Clenbuterol

Clen

Clenbuterol ("Clen") is a long-acting beta-2 adrenergic agonist licensed in some countries as a veterinary bronchodilator and, in a few, for human airway disease. It is not an anabolic steroid and not approved for fat loss or physique/performance use anywhere. People misuse it because chronic beta-2 stimulation drives lipolysis (fat breakdown), mild thermogenesis, and (in animals) skeletal-muscle hypertrophy, but robust human efficacy data for these physique goals do not exist. The main dangers are cardiovascular and metabolic: sustained fast heart rate, palpitations, chest pain, tremor, dangerous drops in potassium/phosphate/magnesium, high blood sugar, and documented biochemical myocardial injury. Because its half-life is very long (about 35 hours in humans), toxic symptoms can persist for a day or more after a single dose, and it accumulates with repeated dosing. Severe cases have involved rhabdomyolysis (muscle breakdown) and death in the setting of polydrug misuse. Human safety data are limited to case reports, poisoning outbreaks, and small pharmacokinetic studies; there are no controlled trials supporting its use for fat loss. Educational information only, not medical advice; it does not create a doctor-patient relationship. These substances carry serious risks; consult a qualified physician and obtain regular bloodwork. 21+ only.

Clinical readoutPED-adjacent · beta2-agonist
Hepatic strainLow
CardiovascularHigh
HPTA suppressionNone
Half-life
35 h
Route
Primarily oral
Evidence
C
Active
Prolonged: plasma level…
35 h2.9 d4.4 d5.8 d7.3 d
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Approximately 35 hours in healthy human volunteers after oral dosing (20-80 micrograms); notably longer than most beta-2 agonists.
Pharmacology

Mechanism of action

Clenbuterol is a selective beta-2 adrenergic receptor agonist. Binding to beta-2 receptors activates adenylate cyclase and raises intracellular cyclic AMP, producing bronchial and vascular smooth-muscle relaxation, hepatic and adipose lipolysis and glycogenolysis (raising blood glucose), and an intracellular shift of potassium (causing hypokalemia). In skeletal muscle, chronic beta-2 stimulation promotes fast-twitch fiber hypertrophy in adult animal models via increased protein synthesis, reduced protein degradation, and altered intracellular signaling (e.g., calcineurin upregulation); this anabolic effect is demonstrated preclinically and is not established in healthy humans. Its long duration of action reflects a halogenated aromatic ring structure that resists rapid metabolism, giving high oral bioavailability and a long plasma half-life. In overdose, the same beta-2 mechanism produces sympathomimetic toxicity: tachycardia, tremor, hypokalemia, hypophosphatemia, hyperglycemia, and (in animal and human reports) myocardial injury and coronary vasospasm.
Kinetics

Pharmacokinetics

Half-life

Approximately 35 hours in healthy human volunteers after oral dosing (20-80 micrograms); notably longer than most beta-2 agonists.

Active duration

Prolonged: plasma levels persist beyond 6 hours after a single dose and steady state is reached within about 4 days of twice-daily dosing, so the drug accumulates. In overdose, symptoms have persisted more than 20 hours even after serum levels fell below assay detection.

Route

Primarily oral (tablets/syrup); also historically inhaled/oral for bronchodilation. Documented only for monitoring and washout reasoning, not for evading drug testing.

Metabolism & clearance

Highly plasma-protein bound (about 89-98%). Hepatic metabolism via oxidative and conjugative pathways (halogenated aromatic ring confers slow clearance); roughly 20% is excreted unchanged in urine over 72 hours. The long half-life means washout takes several days; clearance reasoning here is for clinical monitoring, not test evasion.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Sympathomimetic stimulation: increased heart rate, tremor (especially fine hand tremor), palpitations, restlessness, and headache, reported consistently in human toxicity cases.
  • Metabolic effects: hyperglycemia (raised blood sugar), hypokalemia, hypophosphatemia, and hypomagnesemia due to beta-2 receptor activation.
  • Lipolysis and mild thermogenesis are the reasons for misuse, but there is no adequate controlled human evidence quantifying fat-loss or performance benefit.
  • Skeletal-muscle hypertrophy (fast-twitch fiber enlargement) is documented in adult animal models but not established in healthy humans.
  • Bronchodilation (the licensed therapeutic effect where approved for airway disease).
  • In supervised heart-failure recovery protocols, clenbuterol has been used as one component of combined therapy to promote reverse remodeling. This demonstrates its beta-2 anabolic action on myocardium, but only in a monitored clinical setting.
Safety

Adverse effects by system

Cardiovascular

Prominent and the leading danger: sustained sinus tachycardia (rates ~140/min reported), palpitations, chest pain, and hypotension. In a multistate outbreak of clenbuterol-adulterated heroin, 6 of 34 patients showed biochemical evidence of myocardial injury. Hypokalemia further raises arrhythmia risk. Fatal outcomes with coronary vasospasm have been described in polydrug misuse.

Hepatic

No established direct hepatotoxicity; clenbuterol is not 17-alpha-alkylated and there is no adequate human data demonstrating primary liver injury. Aminotransferases (AST/ALT) can rise secondarily when severe rhabdomyolysis releases muscle enzymes, which is muscle-derived rather than hepatic.

Endocrine / HPTA

Clenbuterol is not a hormone and has no direct androgenic or gonadal action; it does not suppress the hypothalamic-pituitary-testicular axis. Its main endocrine/metabolic effects are hyperglycemia and beta-2-mediated electrolyte shifts (hypokalemia, hypophosphatemia).

Reproductive

No adequate human safety data in the misuse context. As a beta-2 agonist it relaxes uterine smooth muscle (tocolytic-type effect) and crosses the placenta; animal data show transplacental effects on fetal skeletal-muscle development, so use in pregnancy is a concern and unstudied for misuse.

Neuropsychiatric

Anxiety, restlessness, nervousness, tremor, and insomnia are consistent with sympathomimetic/beta-2 stimulation and are reported in human toxicity presentations; no adequate data on longer-term psychiatric effects.

Renal

No established direct nephrotoxicity. Indirect acute kidney injury is a recognized risk when clenbuterol misuse triggers severe rhabdomyolysis; in the reported human rhabdomyolysis case (CK 122,933 U/L) renal function was preserved with supportive care, but rhabdomyolysis can cause AKI.

Hematologic

No established direct hematologic toxicity and no adequate human data indicating clinically significant effects on blood counts or coagulation. Elevated blood lactate has been observed in acute poisoning as part of the metabolic disturbance rather than a primary hematologic effect.

Dermatologic

No well-characterized direct dermatologic toxicity in humans; diaphoresis (sweating) may accompany sympathomimetic stimulation. No adequate human data on specific skin effects.

Recovery

HPTA suppression & recovery

Suppression: None expected via direct hormonal action

Clenbuterol is a beta-2 agonist, not an androgen or hormone, and does not directly suppress the hypothalamic-pituitary-testicular axis, so it does not create a hormonal deficit requiring post-cycle recovery on that basis. No SERM-based recovery is indicated for clenbuterol itself; if it is used alongside hormonal agents, any HPTA concern arises from those other compounds. Only single-SERM approaches are ever in scope, and any recovery or hormonal concern should be evaluated and managed by an endocrinologist.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Serum electrolytes with special attention to potassium, phosphate, and magnesiumBlood glucose12-lead ECG (rate, rhythm, QT)Cardiac troponin if chest pain, dyspnea, or suspected myocardial injuryCreatine kinase (CK) and renal function (creatinine, urinalysis) if muscle pain or dark urine to detect rhabdomyolysisBlood pressure and heart rate monitoring

Cadence: Baseline clinician evaluation before any use, with prompt (same-day/emergency) assessment if symptoms develop; because the half-life is long and levels accumulate, monitoring should account for effects persisting more than a day after the last dose. There is no evidence-based 'safe' monitoring schedule for non-medical use — medical supervision is strongly advised.

Warning signs — seek care
  • Chest pain, severe palpitations, or a persistently racing/irregular heartbeat
  • Shortness of breath or fainting
  • Severe or worsening tremor, agitation, or confusion
  • Muscle pain, weakness, or dark/cola-colored urine (possible rhabdomyolysis)
  • Symptoms of low potassium: profound weakness, cramps, palpitations
  • Any of these warrant stopping use and seeking emergency medical care.
Do not use if

Contraindications

  • Pre-existing cardiovascular disease: coronary artery disease, arrhythmias, tachyarrhythmias, hypertension, cardiomyopathy, or heart failure (outside supervised protocols).
  • Hypokalemia or other electrolyte disturbance, or conditions/medications that lower potassium (clenbuterol worsens hypokalemia and arrhythmia risk).
  • Hyperthyroidism (additive sympathomimetic and metabolic strain).
  • Diabetes or impaired glucose control (clenbuterol raises blood glucose).
  • Pregnancy and breastfeeding (uterine relaxation, placental transfer, fetal effects in animal data; unstudied for misuse).
  • Concurrent use of other stimulants/sympathomimetics or thermogenic agents such as 2,4-dinitrophenol, which has been associated with fatal outcomes when combined.
  • Known seizure disorder or significant anxiety disorder (sympathomimetic aggravation).
Combinations

Interaction profile

  • MajorWith an anabolic steroid: Additive cardiovascular strain
  • MajorWith a stimulant: Additive cardiovascular strain
  • ModerateWith a SARM: Additive cardiovascular strain
  • MajorWith thyroid hormone: Additive cardiovascular strain
  • ModerateWith a GLP-1 / incretin agonist: Additive cardiovascular strain
  • ModerateWith a melanocortin agonist: Additive hypertension
  • MajorWith insulin: Metabolic / glucose
  • MajorWith a QT-prolonging drug: QT prolongation
  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • This is not medical advice. Clenbuterol has no approved human use for fat loss or physique/performance and carries serious cardiovascular risk; the safest choice is not to use it.
  • If used, treat cardiovascular symptoms as emergencies: chest pain, fainting, severe palpitations, or a persistently racing/irregular heartbeat mean stop and seek emergency care immediately.
  • Because the half-life is ~35 hours and the drug accumulates, effects and toxicity can last more than a day after the last dose; 'redosing' because you don't feel it yet risks stacking toxic levels.
  • Watch for low-potassium symptoms (severe weakness, cramps, palpitations) and get electrolytes checked; hypokalemia raises the risk of dangerous heart rhythms.
  • Muscle pain, weakness, or dark/cola-colored urine may signal rhabdomyolysis; seek urgent care and hydration/medical evaluation.
  • Do not combine with other stimulants or with 2,4-dinitrophenol (DNP); such combinations have been linked to death.
  • People with heart disease, arrhythmia, high blood pressure, hyperthyroidism, or diabetes, and anyone pregnant or breastfeeding, should not use it.
  • Get baseline and follow-up bloodwork and a clinician's assessment; absence of data on non-medical use is not evidence of safety.
  • Any hormonal or recovery questions should be directed to an endocrinologist; clenbuterol itself is not hormonal and does not require SERM-based recovery.
Evidence

Citations (12)

Every clinical claim above is tied to a primary source. Overall evidence grade C — graded to the best available evidence for its core claims.

  1. 01

    Clenbuterol is a long-acting beta-2 adrenergic agonist; acute toxicity resembles other beta-2 agonists and can cause prolonged sinus tachycardia (~140/min), hypokalemia, hypophosphatemia, hypomagnesemia, and tremor, with symptoms persisting more than 20 hours even after serum levels fall below detection.

    Case reportPMID 11527226 ↗

  2. 02

    In a multistate outbreak of clenbuterol-adulterated heroin, 34 emergency presentations showed tachycardia, hypotension, chest pain, palpitations, dyspnea, tremor, hyperglycemia, hypokalemia, and raised lactate, and 6 of 34 patients had biochemical evidence of myocardial injury.

    Case seriesPMID 18501476 ↗

  3. 03

    A separate clenbuterol-adulterated heroin outbreak (Richmond, 2015) produced a cluster of severe atypical presentations with laboratory-confirmed clenbuterol exposure in 13 patients.

    Case seriesPMID 28121776 ↗

  4. 04

    Clenbuterol misused for muscle-building alongside exercise caused severe rhabdomyolysis in a human (creatine kinase 122,933 U/L), treated supportively with preserved kidney function; rhabdomyolysis can cause acute kidney injury.

    Case reportPMID 26482831 ↗

  5. 05

    A 17-year-old died after taking 2,4-dinitrophenol and clenbuterol for physique enhancement; clenbuterol is described as a beta-2 agonist causing electrolyte disturbances (hypokalemia, hyperglycemia) and death via coronary vasospasm, and its toxicity in bodybuilding misuse is underestimated.

    Case reportDeath of an apprentice bodybuilder following 2,4-dinitrophenol and clenbuterol intakePMID 32125503 ↗

  6. 06

    In healthy human volunteers, oral clenbuterol (20-80 micrograms) reached peak plasma levels within ~2.5 hours, had a plasma half-life of about 35 hours, reached steady state within ~4 days of twice-daily dosing, was 89-98% protein bound, and had about 20% excreted unchanged in urine over 72 hours.

    CohortPMID 4045696 ↗

  7. 07

    Steady-state human pharmacokinetics of oral clenbuterol (20 micrograms twice daily for 7 days) were characterized in healthy male volunteers, supporting accumulation to steady state with repeated dosing.

    CohortPMID 2807621 ↗

  8. 08

    Clenbuterol has been used as one component of combined pharmacologic therapy (with a left ventricular assist device) in a prospective study to promote myocardial recovery in end-stage heart failure, illustrating its beta-2 action on myocardium in a supervised clinical setting.

    CohortPMID 21242487 ↗

  9. 09

    Beta-agonists with halogenated aromatic ring systems, including clenbuterol, are metabolized by oxidative and conjugative pathways and have long plasma half-lives and high oral potency in humans.

    ReviewPMID 9464898 ↗

  10. 10

    Clenbuterol is a recognized contaminant of meat and dietary sources and a monitored anabolic/doping agent, reflecting its non-medical availability and misuse context.

    ReviewPMID 32727139 ↗

  11. 11

    Acute beta-2 agonist (clenbuterol) administration increases blood glucose and insulin levels, consistent with the hyperglycemia seen in human toxicity.

    PreclinicalPMID 32472192 ↗

  12. 12

    In adult male rats given clenbuterol in drinking water for 4 weeks, fast-twitch skeletal-muscle fibers hypertrophied (10-32% higher body/hindlimb-muscle weights, 44-70% larger fast-fiber cross-sectional area) alongside increased muscle calcineurin content — the mechanistic basis for its anabolic reputation in adult animals (not established in healthy humans).

    PreclinicalPMID 14758479 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice